ZA200803384B - Modified proteases that inhibit complement activation - Google Patents

Modified proteases that inhibit complement activation

Info

Publication number
ZA200803384B
ZA200803384B ZA200803384A ZA200803384A ZA200803384B ZA 200803384 B ZA200803384 B ZA 200803384B ZA 200803384 A ZA200803384 A ZA 200803384A ZA 200803384 A ZA200803384 A ZA 200803384A ZA 200803384 B ZA200803384 B ZA 200803384B
Authority
ZA
South Africa
Prior art keywords
complement activation
inhibit complement
modified proteases
proteases
modified
Prior art date
Application number
ZA200803384A
Other languages
English (en)
Inventor
Edwin L Madison
Ruggles Sandra Waugh
Nguyen Jack
Christopher D Thanos
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Publication of ZA200803384B publication Critical patent/ZA200803384B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21109—Matriptase (3.4.21.109)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
ZA200803384A 2005-10-21 2008-04-16 Modified proteases that inhibit complement activation ZA200803384B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72981705P 2005-10-21 2005-10-21

Publications (1)

Publication Number Publication Date
ZA200803384B true ZA200803384B (en) 2009-01-28

Family

ID=37686157

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200803384A ZA200803384B (en) 2005-10-21 2008-04-16 Modified proteases that inhibit complement activation

Country Status (16)

Country Link
US (3) US20070093443A1 (ko)
EP (3) EP2428218A1 (ko)
JP (2) JP5219819B2 (ko)
KR (3) KR101393946B1 (ko)
CN (2) CN101340928B (ko)
AU (1) AU2006304804B2 (ko)
CA (1) CA2626356C (ko)
ES (2) ES2400306T3 (ko)
HK (1) HK1115815A1 (ko)
IL (1) IL190954A (ko)
MX (1) MX2008004693A (ko)
NO (1) NO20081755L (ko)
NZ (2) NZ595193A (ko)
SI (1) SI1940457T1 (ko)
WO (1) WO2007047995A2 (ko)
ZA (1) ZA200803384B (ko)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
SG166001A1 (en) * 2002-10-02 2010-11-29 Catalyst Biosciences Inc Methods of generating and screening for proteases with altered specificity
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DK1735439T3 (da) 2004-04-12 2012-02-06 Catalyst Biosciences Inc Spaltning af VEGF og VEGF receptor ved hjælp af vild-type og mutant MT-SP1
JP2008522632A (ja) * 2004-12-13 2008-07-03 アレシア・バイオセラピューティクス・インコーポレーテッド 骨再構築のプロセスに関与するポリヌクレオチド及びポリペプチド配列
WO2006090389A2 (en) * 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
DK1937815T3 (en) 2005-09-13 2015-08-03 Nat Res Council Canada Methods and compositions for the modulation of tumor cell activity
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
WO2007141004A1 (en) * 2006-06-09 2007-12-13 Bayer Healthcare Ag Use of adipsin (adn) as a therapeutic or diagnostic target
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
SG175602A1 (en) 2006-07-05 2011-11-28 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
EP3028716B1 (en) 2006-10-10 2020-09-16 Regenesance B.V. Complement inhibition for improved nerve regeneration
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
KR20090122465A (ko) * 2007-03-01 2009-11-30 어드벤스드 비젼 테라피스, 인코포레이티드 염증성 질환의 치료
EP2147096B1 (en) * 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
WO2008131359A1 (en) * 2007-04-20 2008-10-30 Waltham Technologies Inc. Genetically modified biological cells
EP2252317B1 (en) * 2008-02-15 2014-04-09 Tufts University Treatment of macular degeneration
WO2009120760A1 (en) * 2008-03-28 2009-10-01 The Cleveland Clinic Foundation Corin for treating obesity and diabetes
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
PT2293804E (pt) 2008-05-29 2013-08-29 Univ Bologna Alma Mater Vírus herpes simplex (hsv) com tropismo modificado, suas utilizações e processo de preparação
CA2734866A1 (en) * 2008-08-20 2010-02-25 The Trustees Of The University Of Pennsylvania Complement inhibitors for treatment of injury from intracerebral hemorrhage
ES2940323T3 (es) 2008-09-15 2023-05-05 Uniqure Biopharma B V Mutante de polipéptido factor IX, sus usos y un método para su producción
US20100099731A1 (en) * 2008-10-01 2010-04-22 Texas Tech University System Use of Endothelial Interrupters in the Treatment of Neurodegenerative Diseases
CA2741190A1 (en) * 2008-10-21 2010-04-29 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. High-throughput assay for evaluating dipeptidyl peptidase i activity
IT1392551B1 (it) 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica
IT1392567B1 (it) 2008-12-24 2012-03-09 Bioindustry Park Del Canavese S P A Uso di un peptide derivato da er-alfa per il ripristino della sensibilita' a composti antiestrogenici in cellule di tumore mammario
JP2010271078A (ja) * 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
AU2010272483B2 (en) * 2009-07-17 2016-07-21 Omeros Corporation MASP isoforms as inhibitors of complement activation
EP2504363B1 (en) 2009-11-24 2019-05-08 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
AU2011222883B2 (en) 2010-03-05 2016-05-26 Omeros Corporation Chimeric inhibitor molecules of complement activation
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
CA2843684A1 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
JP6108628B2 (ja) 2011-03-29 2017-04-05 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｔｍｐｒｓｓ６遺伝子の発現を阻害する組成物および方法
US9249406B2 (en) 2011-09-08 2016-02-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutated tissue plasminogen activators and uses thereof
CN104159926B (zh) * 2011-12-01 2019-02-01 圆祥生命科技有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
US9822170B2 (en) 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
US20130309753A1 (en) * 2012-05-16 2013-11-21 Saint Louis University Recombinant auto-activating protease precursors
RS61755B1 (sr) * 2012-06-18 2021-05-31 Omeros Corp Kompozicije i postupci za inhibiciju masp-1 i/ili masp-2 i/ili masp-3 za tretman različitih bolesti i poremećaja
ES2704083T3 (es) 2012-07-25 2019-03-14 Catalyst Biosciences Inc Polipéptidos de factor x modificados y usos de los mismos
EP2912065A4 (en) 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
RU2502998C1 (ru) * 2012-11-13 2013-12-27 Федеральное государственное бюджетное учреждение науки Институт физиологии природных адаптаций Уральского отделения Российской академии наук Способ выявления повышенной активированности т-лимфоцитов
GB201303876D0 (en) * 2013-01-29 2013-04-17 Verenium Corp Animal feed enzyme extraction
CN111529708A (zh) 2013-03-15 2020-08-14 夏尔维洛药品公司 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法
KR102234623B1 (ko) 2013-05-22 2021-04-02 알닐람 파마슈티칼스 인코포레이티드 Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법
US10254288B2 (en) * 2013-08-16 2019-04-09 Quidel Corporation Method for species-independent measurement of complement activation in animals
CN114106099B (zh) * 2014-01-31 2024-05-24 西托姆克斯治疗公司 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
WO2016085852A1 (en) 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
WO2016105575A1 (en) 2014-12-23 2016-06-30 Siemens Healthcare Diagnostics Inc. Proteolytic digestion of cardiac troponin i
HRP20230093T1 (hr) 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana anti-c1s protutijela i postupci njihove primjene
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
WO2017127761A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
US10213894B2 (en) 2016-02-26 2019-02-26 Applied Materials, Inc. Method of placing window in thin polishing pad
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
GB201704071D0 (en) * 2017-03-14 2017-04-26 Univ Newcastle Recombinant mature complement factor 1
SG11201912071QA (en) * 2017-06-22 2020-01-30 Catalyst Biosciences Inc Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
CN111465857A (zh) * 2017-08-08 2020-07-28 昆士兰科技大学 诊断早期心力衰竭的方法
CN111491551B (zh) * 2017-09-06 2023-11-17 纽约州立大学研究基金会 用于从流体中去除内毒素和细胞因子的组合物和装置
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US11913960B2 (en) * 2018-05-11 2024-02-27 The University Of Toledo ELISA assay for measuring function of properdin and kits for conducting ELISA assays using anti-properdin antibodies
CN108665111B (zh) * 2018-05-16 2021-08-13 陈孟禹 基于虫态发育与温度关系的胡杨春尺蠖防治期预测方法
CN109001455B (zh) * 2018-06-15 2021-09-10 天津一瑞生物科技股份有限公司 一种肺泡灌洗液样本处理液及处理检测方法
KR102107214B1 (ko) 2018-07-20 2020-05-13 경북대학교 산학협력단 보체 성분 8 감마 단백질 또는 이의 단편을 포함하는 신경염증성 질환 치료용 조성물
WO2020086735A1 (en) * 2018-10-23 2020-04-30 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
PE20211664A1 (es) 2018-12-28 2021-08-26 Catalyst Biosciences Inc Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
IT201900002321A1 (it) * 2019-02-18 2020-08-18 Univ Degli Studi Padova Peptidi con attivita' antitumorale
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
MX2023001764A (es) * 2020-08-14 2023-04-25 Orchard Therapeutics Europe Ltd Composiciones y métodos para tratar o prevenir el angioedema hereditario.
EP4000596A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4274604A1 (en) * 2021-01-08 2023-11-15 Vertex Pharmaceuticals Incorporated Factor b proteases
IL307926A (en) 2021-04-26 2023-12-01 Alnylam Pharmaceuticals Inc Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them
WO2022236176A2 (en) * 2021-05-07 2022-11-10 City Of Hope Fxa protein for treating and/or preventing covid-19
WO2023172654A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Method of protease detection

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
FI88932C (fi) * 1982-04-15 1993-07-26 Genentech Inc Framstaellning av funktionellt maenskligt urokinasprotein
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4624846A (en) 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
EP0238473A3 (en) 1986-03-18 1989-06-07 Monsanto Company Serine protease inhibitors
FI100106B (fi) * 1986-12-05 1997-09-30 Novartis Ag Menetelmä plasminogeenin yksisäikeisen yhdistelmäaktivaattorin valmist amiseksi
AU1893988A (en) * 1987-07-13 1989-01-19 Collaborative Research Inc. Nonglycosylated plasminogen activator and method of preparation
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
US6271012B1 (en) * 1989-10-11 2001-08-07 Genencor International, Inc. Protease muteins and their use in detergents
US5256643A (en) * 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5869615A (en) * 1994-01-03 1999-02-09 Washington University Modified complement proteases
GB9618960D0 (en) * 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
US6969601B2 (en) * 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
CA2305016A1 (en) * 1997-09-24 1999-04-01 Regents Of The University Of Minnesota Human complement c3-degrading proteinase from streptococcus pneumoniae
DE19743683A1 (de) 1997-10-02 1999-04-08 Basf Ag Verfahren zur Änderung der Substratspezifität von Enzymen
EP1056877A1 (en) * 1998-02-27 2000-12-06 Boehringer Ingelheim Pharmaceuticals Inc. Self-regulated apoptosis of inflammatory cells by gene therapy
US6902918B1 (en) 1998-05-21 2005-06-07 California Institute Of Technology Oxygenase enzymes and screening method
IL142017A0 (en) 1998-09-24 2002-03-10 Univ Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
AU1619400A (en) 1998-11-10 2000-05-29 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimization of plantphenotypes
US7273925B1 (en) * 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
WO2000053232A1 (en) * 1999-03-12 2000-09-14 Georgetown University Matriptase, a serine protease and its applications
US20030186329A1 (en) * 1999-03-22 2003-10-02 The Scripps Research Institute Use of substrate subtraction libraries to distinguish enzyme specificities
EP1179052A4 (en) 1999-05-07 2004-12-15 Human Genome Sciences Inc SERINE PROTEASES
DE19943177C2 (de) * 1999-09-09 2002-10-24 Dieter Jenne Verfahren zur Herstellung von aktiven Serienproteasen und inaktiven Varianten
AU7476900A (en) 1999-09-09 2001-04-10 Millennium Pharmaceuticals, Inc. 26176, a novel calpain protease and uses thereof
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
AU1436401A (en) 1999-10-21 2001-05-14 Board Of Trustees Of The University Of Arkansas, The RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof
GB9929061D0 (en) 1999-12-08 2000-02-02 Medical Res Council Methods of producing novel enzymes
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6797504B1 (en) 2000-09-08 2004-09-28 Dendreon San Diego Llc Inhibitors of serine protease activity of matriptase or MTSP1
EP1252300B1 (en) 2000-02-03 2011-01-19 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US20020031801A1 (en) 2000-03-24 2002-03-14 Millennium Pharmaceuticals, Inc. 18806, a novel trypsin serine protease-like molecule and uses thereof
EP1283719B1 (de) * 2000-04-22 2007-09-05 PharmedArtis GmbH Apoptotika
WO2001091798A2 (en) * 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
AU2001265092A1 (en) 2000-06-02 2001-12-17 Regents Of The University Of California Profiling of protease specificity using combinatorial fluorogenic substrate libraries
AU2001278488A1 (en) 2000-07-25 2002-02-05 Bayer Aktiengesellschaft Regulation of human matriptase-like serine protease
US7157596B2 (en) 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
EP1383884A4 (en) 2001-03-22 2004-12-15 Dendreon Corp SERINE PROTEASE CVSP14 CODING NUCLEIC ACID MOLECULES, THE CODED POLYPEPTIDES AND METHODS THEREOF
WO2002077267A2 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
KR20040080940A (ko) 2001-05-14 2004-09-20 덴드레온 코포레이션 트랜스막 세린 프로테아제 10을 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
WO2002095007A2 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
US20030134298A1 (en) * 2001-07-03 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
JP2004535202A (ja) * 2001-07-17 2004-11-25 リサーチ　ディベロップメント　ファンデーション アポトーシス促進性蛋白質を含む治療剤
WO2003031585A2 (en) 2001-10-09 2003-04-17 Dendreon Corporation Transmembrane serine protease 25
AU2002357004A1 (en) 2001-11-20 2003-06-10 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20040072276A1 (en) * 2002-05-10 2004-04-15 Direvo BioTech AG. Process for generating sequence-specific proteases by directed evolution and use thereof
EP1361284A1 (en) 2002-05-10 2003-11-12 Direvo Biotech AG Process for generating sequence-specific proteases by directed evolution and use thereof
AU2003269880A1 (en) 2002-05-21 2003-12-22 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
WO2004005471A2 (en) 2002-07-02 2004-01-15 Dendreon Corporation Serine protease 16
US7666627B2 (en) 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
SG166001A1 (en) * 2002-10-02 2010-11-29 Catalyst Biosciences Inc Methods of generating and screening for proteases with altered specificity
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US20040115727A1 (en) 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
CA2426115A1 (en) * 2003-04-18 2004-10-18 Victor Gurewich Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
US7070958B2 (en) * 2003-04-18 2006-07-04 Thrombolytic Science, Inc. Methods of making pro-urokinase mutants
CA2529589A1 (en) 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the pharmaceutical or diagnostic use thereof
US7335504B2 (en) * 2003-06-18 2008-02-26 Direvo Biotechnology Ag Engineered enzymes and uses thereof
IL156566A0 (en) * 2003-06-19 2004-01-04 Hadasit Med Res Service Urokinase plasminogen activator derived octapeptide in the treatment of multiple sclerosis
CA2588965C (en) * 2003-12-18 2013-01-22 Werner Seeger Novel chimeric plasminogen activators and their pharmaceutical use
EP1735438A2 (en) 2004-04-12 2006-12-27 Catalyst Biosciences Cleavage of vegf and vegf receptor by wild-type and mutant proteases
DK1735439T3 (da) 2004-04-12 2012-02-06 Catalyst Biosciences Inc Spaltning af VEGF og VEGF receptor ved hjælp af vild-type og mutant MT-SP1
US20060029590A1 (en) * 2004-06-10 2006-02-09 Christopher Thanos Administration of neutral endopeptidase to treat inflammatory bowel disease
TW200635946A (en) * 2004-12-20 2006-10-16 Abgenix Inc Binding proteins specific for human matriptase
EP1827486A2 (en) 2004-12-22 2007-09-05 Direvo Biotech AG Targeted use of engineered enzymes
EP1726643A1 (en) 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
SG175602A1 (en) 2006-07-05 2011-11-28 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
EP2147096B1 (en) * 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
ES2704083T3 (es) 2012-07-25 2019-03-14 Catalyst Biosciences Inc Polipéptidos de factor x modificados y usos de los mismos
US10411005B2 (en) 2017-11-15 2019-09-10 Taiwan Semiconductor Manufacturing Co., Ltd. Intelligent diode structures

Also Published As

Publication number Publication date
JP2013013420A (ja) 2013-01-24
NZ595193A (en) 2013-09-27
KR101691692B1 (ko) 2016-12-30
CN101340928A (zh) 2009-01-07
WO2007047995A3 (en) 2007-10-04
JP2009512451A (ja) 2009-03-26
SI1940457T1 (sl) 2013-04-30
CN102430117A (zh) 2012-05-02
KR101393946B1 (ko) 2014-05-12
IL190954A (en) 2017-07-31
US20120244139A1 (en) 2012-09-27
EP2428218A1 (en) 2012-03-14
WO2007047995A2 (en) 2007-04-26
KR20110043772A (ko) 2011-04-27
US9795655B2 (en) 2017-10-24
ES2400306T3 (es) 2013-04-09
CA2626356C (en) 2017-08-22
NZ606504A (en) 2014-08-29
CN102430117B (zh) 2018-07-24
AU2006304804A1 (en) 2007-04-26
HK1115815A1 (en) 2008-12-12
AU2006304804B2 (en) 2011-06-02
US20070093443A1 (en) 2007-04-26
EP2433642A3 (en) 2012-07-11
EP2433642A2 (en) 2012-03-28
KR20140007501A (ko) 2014-01-17
JP5219819B2 (ja) 2013-06-26
EP1940457A2 (en) 2008-07-09
CA2626356A1 (en) 2007-04-26
EP1940457B1 (en) 2012-12-12
EP2433642B1 (en) 2016-12-07
JP5860789B2 (ja) 2016-02-16
CN101340928B (zh) 2011-12-21
KR20080073710A (ko) 2008-08-11
IL190954A0 (en) 2011-08-01
KR101126423B1 (ko) 2012-07-11
ES2611608T3 (es) 2017-05-09
MX2008004693A (es) 2008-09-03
NO20081755L (no) 2008-07-21
US20140242062A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
HK1115815A1 (en) Modified proteases that inhibit complement activation
HK1145022A1 (en) Processes
LT1981519T (lt) Proteazės slopinimas
EP1775630A4 (en) CASE
GB0523969D0 (en) Inductivwe component
EP1848299A4 (en) BOX
PL1917342T3 (pl) Środki czyszczące
GB2440699B (en) Combination dolly-pallet
EP1961129A4 (en) ACTIVATION CIRCUIT WITHOUT CLOCK
GB0523041D0 (en) Combination
GB0511590D0 (en) Anti-thrombotic agents
GB0523040D0 (en) Combination
GB0507255D0 (en) Low k8
GB0523899D0 (en) The one
AU3292P (en) DP303 Dianella prunina
GB0505299D0 (en) Forking applications
GB0510980D0 (en) IT structuring
GB0507628D0 (en) Protease inhibitors
GB0507627D0 (en) Protease inhibitors
GB0510544D0 (en) Component
GB0524167D0 (en) Hologram
AU302464S (en) Case
GB0508237D0 (en) Combination
GB0501914D0 (en) Keyboards
GB0505157D0 (en) Keyboards